PRECIGEN, INC. Selling, General and Administrative Expense
PRECIGEN, INC. (PGEN) reported Selling, General and Administrative Expense of $22.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-04
- PRECIGEN, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $22.25M, a 37.91% increase year-over-year.
- PRECIGEN, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $21.05M, a 70.31% increase year-over-year.
- PRECIGEN, INC. selling, general and administrative expense for the quarter ending 2025-06-30 was $16.13M.
- PRECIGEN, INC. selling, general and administrative expense for the quarter ending 2025-03-31 was $12.36M.
- PRECIGEN, INC. selling, general and administrative expense for fiscal 2025 was $70.13M, a 69.83% increase from fiscal 2024.
- PRECIGEN, INC. selling, general and administrative expense for fiscal 2024 was $41.29M, a 2.17% increase from fiscal 2023.
- PRECIGEN, INC. selling, general and administrative expense for fiscal 2023 was $40.41M.
- PRECIGEN, INC. selling, general and administrative expense for fiscal 2018 was $137.81M, a 5.68% decline from fiscal 2017.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.25M 10-Q · filed 2026-08-04 | $43.30M 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | $21.05M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $70.13M 10-K · filed 2026-03-25 | |||
| 2025-06-30 | $16.13M 10-Q · filed 2026-08-04 | $28.49M 10-Q · filed 2026-08-04 | ||
| 2025-03-31 | $12.36M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $41.29M 10-K · filed 2026-03-25 | |||
| 2023-12-31 | $40.41M 10-K · filed 2026-03-25 | |||
| 2019-09-30 | $24.74M 10-Q · filed 2019-11-12 | $46.22M derived: sum of 2 quarters · filed 2019-11-12 | $79.82M 10-Q · filed 2019-11-12 | $104.75M derived: sum of 4 quarters · filed 2019-11-12 |
| 2019-06-30 | $21.48M 10-Q · filed 2019-08-09 | $55.08M 10-Q · filed 2019-08-09 | $80.01M derived: sum of 3 quarters · filed 2019-08-09 | $118.72M derived: sum of 4 quarters · filed 2019-11-12 |
| 2019-03-31 | $33.59M 10-Q · filed 2019-05-09 | $58.53M derived: sum of 2 quarters · filed 2019-05-09 | $97.24M derived: sum of 3 quarters · filed 2019-11-12 | $131.66M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-12-31 | $24.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $63.64M derived: sum of 2 quarters · filed 2019-11-12 | $98.07M derived: sum of 3 quarters · filed 2019-11-12 | $137.81M 10-K · filed 2019-03-01 |
| 2018-09-30 | $38.71M 10-Q · filed 2019-11-12 | $73.14M derived: sum of 2 quarters · filed 2019-11-12 | $112.87M 10-Q · filed 2019-11-12 | $145.72M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $34.43M 10-Q · filed 2019-08-09 | $74.16M 10-Q · filed 2019-08-09 | $107.01M derived: sum of 3 quarters · filed 2019-08-09 | $146.29M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $39.74M 10-Q · filed 2019-05-09 | $72.58M derived: sum of 2 quarters · filed 2019-05-09 | $111.86M derived: sum of 3 quarters · filed 2019-05-09 | $150.70M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $32.84M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $72.12M derived: sum of 2 quarters · filed 2019-03-01 | $110.97M derived: sum of 3 quarters · filed 2019-03-01 | $146.10M 10-K · filed 2019-03-01 |
| 2017-09-30 | $39.28M 10-Q · filed 2018-11-08 | $78.12M derived: sum of 2 quarters · filed 2018-11-08 | $113.26M 10-Q · filed 2018-11-08 | $148.62M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $38.84M 10-Q · filed 2018-08-13 | $73.98M 10-Q · filed 2018-08-13 | $109.34M derived: sum of 3 quarters · filed 2019-03-01 | $143.16M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $35.14M 10-Q/A · filed 2018-08-13 | $70.50M derived: sum of 2 quarters · filed 2019-03-01 | $104.31M derived: sum of 3 quarters · filed 2019-03-01 | $134.57M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $35.36M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $69.17M derived: sum of 2 quarters · filed 2019-03-01 | $99.44M derived: sum of 3 quarters · filed 2019-03-01 | $142.32M 10-K · filed 2019-03-01 |
| 2016-09-30 | $33.81M 10-Q · filed 2017-11-09 | $64.08M derived: sum of 2 quarters · filed 2017-11-09 | $106.96M 10-Q · filed 2017-11-09 | $141.69M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $30.26M 10-Q · filed 2017-08-09 | $73.14M 10-Q · filed 2017-08-09 | $107.88M derived: sum of 3 quarters · filed 2018-03-01 | $130.90M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $42.88M 10-Q · filed 2017-05-10 | $77.62M derived: sum of 2 quarters · filed 2018-03-01 | $100.64M derived: sum of 3 quarters · filed 2018-03-01 | $124.31M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $34.74M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $57.76M derived: sum of 2 quarters · filed 2018-03-01 | $81.43M derived: sum of 3 quarters · filed 2018-03-01 | $109.06M 10-K · filed 2018-03-01 |
| 2015-09-30 | $23.02M 10-Q · filed 2016-11-09 | $46.69M derived: sum of 2 quarters · filed 2016-11-09 | $74.32M 10-Q · filed 2016-11-09 | $94.10M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $23.67M 10-Q · filed 2016-08-09 | $51.30M 10-Q · filed 2016-08-09 | $71.08M derived: sum of 3 quarters · filed 2017-03-01 | $85.93M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $27.63M 10-Q · filed 2016-05-10 | $47.41M derived: sum of 2 quarters · filed 2017-03-01 | $62.26M derived: sum of 3 quarters · filed 2017-03-01 | $77.64M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $19.78M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $34.63M derived: sum of 2 quarters · filed 2017-03-01 | $50.01M derived: sum of 3 quarters · filed 2017-03-01 | $63.65M 10-K · filed 2017-03-01 |
| 2014-09-30 | $14.85M 10-Q · filed 2015-11-09 | $30.23M derived: sum of 2 quarters · filed 2015-11-09 | $43.87M 10-Q · filed 2015-11-09 | $56.17M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $15.38M 10-Q · filed 2015-08-10 | $29.02M 10-Q · filed 2015-08-10 | $41.31M derived: sum of 3 quarters · filed 2016-02-29 | $48.72M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $13.63M 10-Q · filed 2015-05-11 | $25.93M derived: sum of 2 quarters · filed 2016-02-29 | $33.34M derived: sum of 3 quarters · filed 2016-02-29 | |
| 2013-12-31 | $12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $19.70M derived: sum of 2 quarters · filed 2016-02-29 | $33.62M 10-K · filed 2016-02-29 | |
| 2013-09-30 | $7.41M 10-Q · filed 2014-11-13 | $21.32M 10-Q · filed 2014-11-13 | ||
| 2012-12-31 | $24.90M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |